혈액종양내과 김승태 교수

학력
2011.02	성균관대학교 대학원 의학과 박사 졸업
2005.02	성균관대학교 대학원 의학과 석사 졸업
2001.02	동국대학교 의과대학 졸업

경력
2023.03 ~현재	삼성서울병원 혈액종양내과 교수
2017.03 ~ 2023.02	삼성서울병원 혈액종양내과 부교수
2014.03 ~ 2017.02	삼성서울병원 혈액종양내과 전임대우조교수
2013.11 ~ 2014.02	삼성서울병원 혈액종양내과 진료조교수
2013.03 ~ 2013.10	고려대학교 의과대학 내과 조교수
2010.03 ~ 2013.02	고려대학교 안암병원 종양내과 임상조교수
2009.05 ~ 2010.02	삼성서울병원 혈액종양내과 임상강사
2007.05 ~ 2009.04	보건산업진흥원 연구원
2002.03 ~ 2006.02	삼성서울병원 내과 레지던트 과정 수료
2001.03 ~ 2002.02	삼성서울병원 인턴 과정 수료

ONCOL RES 2025 10.32604/or.2024.049054 Comprehensive molecular characterization to predict immunotherapy response in advanced biliary tract cancer: a phase II trial of pembrolizumab Kim, R; Park, JK; Kwon, M; An, M; Hong, JY; Park, JO; Lim, SH; Kim, ST

View PubMed

PATHOL RES PRACT 2024 10.1016/j.prp.2024.155473 Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis Choi, DH; Jang, HL; Lim, SH; Kim, ST; Hong, JY; Park, SH; Park, JO; Kim, DG; Kim, KM; Lee, J

View PubMed

FRONT ONCOL 2024 10.3389/fonc.2024.1450732 TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice Shin, JE; Lim, SH; Lee, J; Lim, HY; Park, YS; Kim, ST

View PubMed

CANCERS 2024 10.3390/cancers16172969 The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer Lim, SH; Kim, MJ; Lee, J; Lim, HY; Kang, WK; Kim, ST

View PubMed

WORLD J GASTRO ONCOL 2024 10.4251/wjgo.v16.i8.3521 Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1 Kang, SW; Lim, SH; Kim, MJ; Lee, J; Park, YS; Lim, HY; Kang, WK; Kim, ST

View PubMed

TRANSL CANCER RES 2024 10.21037/tcr-24-20 CDK4/6 inhibition to resensitize BRAF/EGFR inhibitor in patient-derived BRAF/PTEN-mutant colon cancer cells Lim, SH; Lee, SY; Hong, JY; Lee, J; Kim, ST

View PubMed

CANCER LETT 2024 10.1016/j.canlet.2024.217041 The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial Lim, SH; Saluja, A; Vickers, S; Hong, JY; Kim, ST; Lavania, S; Pandey, S; Gupta, VK; Velagapudi, MR; Lee, J

View PubMed

ANTICANCER RES 2024 10.21873/anticanres.17015 DNA Checkpoint Gene Mutation as a Biomarker for Immune Checkpoint Inhibitor Therapy in Advanced Biliary Tract Cancer Shin, JE; Kim, ST

View PubMed

CANCER DISCOV 2024 10.1158/2159-8290.CD-23-0857 Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer An, M; Mehta, A; Min, BH; Heo, YJ; Wright, SJ; Parikh, M; Bi, L; Lee, H; Kim, TJ; Lee, SY; Moon, J; Park, RJ; Strickland, MR; Park, WY; Kang, WK; Kim, KM; Kim, ST; Klempner, SJ; Lee, J

View PubMed

J CANCER RES THER 2024 10.4103/jcrt.jcrt_2698_22 Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial) Kim, HR; Lee, SJ; Ahn, MS; Kim, JE; Kang, MJ; Hong, JY; Lee, J; Kim, ST

View PubMed

BIOMATERIALS 2024 10.1016/j.biomaterials.2024.122504 Patient-derived tumor spheroid-induced angiogenesis preclinical platform for exploring therapeutic vulnerabilities in cancer Ko, JH; Hyung, S; Heo, YJ; Jung, SM; Kim, ST; Park, SH; Hong, JY; Lim, SH; Kim, KM; Yoo, S; Li Jeon, N; Lee, JY

View PubMed

J GASTROINTEST ONCOL 2023 10.21037/jgo-23-598 The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer Jeon, Y; Lim, SH; Lee, J; Kang, WK; Jang, JY; Jeong, SY; Choi, D; Kim, ST

View PubMed

J CLIN ONCOL 2023 10.1200/JCO.23.00606 Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study Nakamura, Y; Mizuno, N; Sunakawa, Y; Canon, JL; Galsky, MD; Hamilton, E; Hayashi, H; Jerusalem, G; Kim, ST; Lee, KW; Fonkoua, LAK; Monk, BJ; Nguyen, D; Oh, DY; Okines, A; O'Malley, DM; Pohlmann, P; Reck, M; Shin, SJ; Sudo, K; Takahashi, S; Van Marcke, C; Yu, EY; Groisberg, R; Ramos, J; Tan, S; Stinchcombe, TE; Bekaii-Saab, T

View PubMed

BIOMEDICINES 2023 10.3390/biomedicines11123264 Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data Lim, SH; Jung, J; Hong, JY; Kim, ST; Park, SH; Park, JO; Kim, KM; Lee, J

View PubMed

BIOMEDICINES 2023 10.3390/biomedicines11123172 Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer Byeon, S; Jung, J; Kim, ST; Kim, KM; Lee, J

View PubMed

J GASTROINTEST ONCOL 2023 10.21037/jgo-23-418 Effect of ramucirumab plus paclitaxel in advanced gastric cancer according to the status of programmed cell death-ligand 1 (PD-L1) expression Choi, DH; Lee, J; Lim, HY; Kang, WK; Jang, JY; Jeon, Y; Jeong, SY; Jung, YJ; Kim, ST

View PubMed

BIOMEDICINES 2023 10.3390/biomedicines11113097 The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy Shin, MK; Choi, MG; Kim, ST; Kang, WK; Sohn, TS; An, JY; Lee, JH; Lee, JY

View PubMed

SCI ADV 2023 10.1126/sciadv.adk1098 Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer Hyung, S; Ko, J; Heo, YJ; Blum, SM; Kim, ST; Park, SH; Park, JO; Kang, WK; Lim, HY; Klempner, SJ; Lee, J

View PubMed

ONCOL RES 2023 10.32604/or.2023.030374 Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer Lim, SH; Cho, HJ; Kim, KM; Lim, HY; Kang, WK; Lee, J; Park, YS; Kim, HC; Kim, ST

View PubMed

CANCER MED-US 2023 10.1002/cam4.6472 Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer Shin, M; Ahn, S; Jung, J; Hyung, S; Kim, KM; Kim, ST; Kang, WK; Lee, J

View PubMed

ANTICANCER RES 2023 10.21873/anticanres.16607 Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study Lim, SH; Hong, JY; Park, JO; Park, YS; Kim, ST

View PubMed

J GASTROINTEST ONCOL 2023 10.21037/jgo-23-375 Effect of human epidermal growth factor receptor 2 overexpression in metastatic colorectal cancer on standard chemotherapy outcomes Jang, JY; Jeon, YK; Jeong, SY; Lim, SH; Park, YS; Lim, HY; Lee, JY; Kim, ST

View PubMed

J GASTRIC CANCER 2023 10.5230/jgc.2023.23.e29 The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer Jang, JY; Jeon, Y; Jeong, SY; Lim, SH; Kang, WK; Lee, J; Kim, ST

View PubMed

JCO PRECIS ONCOL 2023 10.1200/PO.22.00537 Clinical Implication of HER2 Aberration in Patients With Metastatic Cancer Using Next-Generation Sequencing: A Pan-Tumor Analysis Jung, J; Kim, ST; Ko, J; Hong, JY; Park, JO; Ha, SY; Lee, J

View PubMed

J GASTROINTEST ONCOL 2023 10.21037/jgo-22-1190 Tumor mutation burden in gastro-entero-pancreatic-neuroendocrine neoplasms Jeong, SY; Park, YS; Lee, JY; Jang, J; Jeon, Y; Jung, YJ; Choi, D; Hong, JHY; Kim, ST

View PubMed

MOL IMAGING BIOL 2023 10.1007/s11307-023-01832-7 A Machine Learning Approach Using [F-18]FDG PET-Based Radiomics for Prediction of Tumor Grade and Prognosis in Pancreatic Neuroendocrine Tumor Park, YJ; Park, YS; Kim, ST; Hyun, SH

View PubMed

THER ADV GASTROENTER 2023 10.1177/17562848231170484 The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation Jeong, SY; Hong, JY; Park, JO; Park, YS; Lim, HY; Jang, JY; Jeon, Y; Kim, ST

View PubMed

ESMO OPEN 2023 10.1016/j.esmoop.2023.101558 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer Yoshino, T; Cervantes, A; Bando, H; Martinelli, E; Oki, E; Xu, RH; Mulansari, NA; Babu, KG; Lee, MA; Tan, CK; Cornelio, G; Chong, DQ; Chen, LT; Tanasanvimon, S; Prasongsook, N; Yeh, KH; Chua, C; Sacdalan, MD; Sow, WJ; Kim, ST; Chacko, RT; Syaiful, RA; Zhang, SZ; Curigliano, G; Mishima, S; Nakamura, Y; Ebi, H; Sunakawa, Y; Takahashi, M; Baba, E; Peters, S; Ishioka, C; Pentheroudakis, G

View PubMed

CANCER MED-US 2023 10.1002/cam4.5530 Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers Kim, JE; Kim, H; Kim, B; Chung, HG; Chung, HH; Kim, KM; Kim, SH; Jeong, WK; Kim, YK; Min, JH; Heo, JS; Han, IW; Shin, SH; Park, HC; Yu, JI; Park, JO; Kim, ST; Hong, JY; Lee, SH; Lee, KH; Lee, JK; Lee, KT; Jang, KT; Park, JK

View PubMed

CANCER RES TREAT 2023 10.4143/crt.2021.1527 A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer Jo, H; Kim, ST; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Il Yu, J; Park, HC; Choi, DH; Park, Y; Cho, YB; Huh, JW; Yun, SH; Kim, HC; Lee, WY; Kang, WK

View PubMed

J CLIN ONCOL 2022 10.1200/JCO.21.02962 Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07 Kim, ST; Kim, SY; Lee, J; Yun, SH; Kim, HC; Lee, WY; Kim, TW; Hong, YS; Lim, SB; Baek, JY; Oh, JH; Ahn, JB; Shin, SJ; Han, SW; Kim, SG; Kang, SY; Sym, SJ; Zang, DY; Kim, YH; Choi, IS; Kang, JH; Kim, MJ; Park, YS

View PubMed

J AM ACAD DERMATOL 2022 10.1016/j.jaad.2022.07.057 First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma Kim, CG; Kim, M; Hwang, J; Kim, ST; Jung, M; Kim, KH; Kim, KH; Chang, JS; Koom, WS; Roh, MR; Chung, KY; Kim, TM; Kim, SK; Lee, J; Shin, SJ

View PubMed

PATHOL ONCOL RES 2022 10.3389/pore.2022.1610697 MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer Ko, J; Jung, J; Kim, ST; Hong, JY; Park, S; Park, JO; Park, YS; Lim, HY; Ahn, S; Kim, KM; Kang, WK; Lee, J

View PubMed

ESMO OPEN 2022 10.1016/j.esmoop.2022.100563 Margetuximab with retifanlimab as first-line therapy in HER2D/PD-L1D unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A Catenacci, DVT; Kang, YK; Yoon, HH; Shim, BY; Kim, ST; Oh, DY; Spira, AI; Ulahannan, SV; Avery, EJ; Boland, PM; Chao, J; Chung, HC; Gardner, F; Klempner, SJ; Lee, KW; Oh, SC; Peguero, J; Sonbol, MB; Shen, L; Moehler, M; Sun, J; Li, D; Rosales, MK; Park, H

View PubMed

THER ADV GASTROENTER 2022 10.1177/17562848221117638 Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer Kim, H; Kim, R; Jo, H; Kim, HR; Hong, J; Ha, SY; Park, JO; Kim, ST

View PubMed

CLIN ONCOL-UK 2022 10.1016/j.clon.2022.02.011 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer Jo, H; Lee, MS; Lee, YP; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

View PubMed

CANCERS 2022 10.3390/cancers14143440 Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors Kim, HR; Kang, JH; Kim, SH; Kim, ST; Kim, I; Min, YJ; Shin, SH; Oh, SY; Lee, GW; Lee, JH; Ji, JH; Huh, SJ; Lee, S

View PubMed

J IMMUNOTHER CANCER 2022 10.1136/jitc-2022-005041 Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer Kwon, M; Kim, G; Kim, R; Kim, KT; Kim, ST; Smith, S; Mortimer, PGS; Hong, JY; Loembe, AB; Irurzun-Arana, I; Koulai, L; Kim, KM; Kang, WK; Dean, E; Park, WY; Lee, J

View PubMed

J IMMUNOTHER CANCER 2022 10.1136/jitc-2022-004879 Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study Shui, IM; Liu, XQ; Zhao, Q; Kim, ST; Sun, Y; Yearley, JH; Choudhury, T; Webber, AL; Krepler, C; Cristescu, R; Lee, J

View PubMed

BIOMEDICINES 2022 10.3390/biomedicines10071565 Clinical Significance of Preoperative Hematological Parameters in Patients with D2-Resected, Node-Positive Stomach Cancer Park, JS; Yu, JI; Lim, DH; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM

View PubMed

CANCER DISCOV 2022 10.1158/2159-8290.CD-21-0888 Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer Kim, R; An, M; Lee, H; Mehta, A; Heo, YJ; Kim, KM; Lee, SY; Moon, J; Kim, ST; Min, BH; Kim, TJ; Rha, SY; Kang, WK; Park, WY; Klempner, SJ; Lee, J

View PubMed

ANN SURG ONCOL 2022 10.1245/s10434-022-11592-3 Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY

View PubMed

ANN SURG ONCOL 2022 10.1245/s10434-022-11688-w ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY

View PubMed

J ONCOL 2022 10.1155/2022/9714570 Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing Hyung, S; Han, B; Jung, J; Kim, ST; Hong, JY; Park, SH; Zang, DY; Park, JO; Park, YS; Kim, KM; Kang, WK; Lee, J

View PubMed

J CANCER 2022 10.7150/jca.67050 Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial Kim, R; Ji, JH; Kim, JH; Hong, JY; Lim, HY; Kang, WK; Lee, J; Kim, ST

View PubMed

FRONT ONCOL 2022 10.3389/fonc.2022.834104 HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer Kim, H; Kim, R; Kim, HR; Jo, H; Kim, H; Ha, SY; Park, JO; Park, YS; Kim, ST

View PubMed

CANCER RES TREAT 2022 10.4143/crt.2021.1115 Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group Yoon, S; Kim, M; Hong, YS; Kim, HS; Kim, ST; Kim, J; Yun, H; Yoo, C; Ahn, HK; Kim, HS; Lee, IH; Kim, IH; Park, I; Jeong, JH; Cheon, J; Kim, JW; Yun, J; Lim, SM; Cha, Y; Jang, SJ; Zang, DY; Kim, TW; Kang, JH; Kim, JH

View PubMed

ANN ONCOL 2022 10.1016/j.annonc.2021.10.009 Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy Kim, R; Kwon, M; An, M; Kim, ST; Smith, SA; Loembe, AB; Mortimer, PGS; Armenia, J; Lukashchuk, N; Shah, N; Dean, E; Park, WY; Lee, J

View PubMed

EUR RADIOL 2021 10.1007/s00330-021-08094-3 2021 Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer Cha¹, DI; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Kim, SW; Choi, D

View PubMed

NATURE 2021 10.1038/s41586-021-03515-1 2021 ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Yen¹, I; Shanahan, F; Lee, J; Hong, YS; Shin, SJ; Moore, AR; Sudhamsu, J; Chang, MT; Bae, I; Dela Cruz, D; Hunsaker, T; Klijn, C; Liau, NPD; Lin, E; Martin, SE; Modrusan, Z; Piskol, R; Segal, E; Venkatanarayan, A; Ye, X; Yin, JP; Zhang, LX; Kim, JS; Lim, HS; Kim, KP; Kim, YJ; Han, HS; Lee, SJ; Kim, ST; Jung, M; Hong, YH; Noh, YS; Choi, M; Han, O; Nowicka, M; Srinivasan, S; Yan, YB; Kim, TW; Malek, S

View PubMed

CANCER RES TREAT 2021 10.4143/crt.2020.1233 2021 Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion Yoo¹, C; Oh, CR; Kim, ST; Bae, WK; Choi, HJ; Oh, D; Lee, MA; Ryoo, BY

View PubMed

INVEST NEW DRUG 2021 10.1007/s10637-021-01110-9 2021 A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer Jeong¹, H; Hong, YS; Kim, JE; Lim, HS; Ahn, JB; Shin, SJ; Park, YS; Kim, ST; Han, SW; Kim, TY; Kim, TW

View PubMed

ONCOLOGY-BASEL 2021 10.1159/000514404 2021 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim¹, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

View PubMed

ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 2021 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park¹, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK

View PubMed

THER ADV MED ONCOL 2021 10.1177/1758835921992992 2021 Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors Kim¹, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST

View PubMed

NAT COMMUN 2021 10.1038/s41467-021-21299-w 2021 Chromatin accessibility of circulating CD8(+) T cells predicts treatment response to PD-1 blockade in patients with gastric cancer Shin¹, HM; Kim, G; Kim, S; Sim, JH; Choi, J; Kim, M; Kwon, M; Ye, SK; Lee, DS; Cho, SW; Kim, ST; Lee, J; Kim, HR

View PubMed

ESMO OPEN 2021 10.1016/j.esmoop.2020.100002 2021 Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment Byeon¹, S; Cho, HJ; Jang, KT; Kwon, M; Lee, J; Kim, ST

View PubMed

IN VIVO 2021 10.21873/invivo.12284 2021 ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy Kim¹, H; Kim, ST; Yoo, KH; Hong, JY; Park, YS; Lim, HY; Park, JO

View PubMed

GENOME MED 2021 10.1186/s13073-021-00826-w 2021 Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial Kim¹, ST; Sa, JK; Oh, SY; Kim, K; Hong, JY; Kang, WK; Kim, KM; Lee, J

View PubMed

CANCERS 2021 10.3390/cancers13010059 2021 Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses Park¹, JS; Il Yu, J; Lim, D; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM

View PubMed

J CANCER 2021 10.7150/jca.49176 2021 Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer Kim¹, J; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

View PubMed

FRONT ONCOL 2021 10.3389/fonc.2021.792340 The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers Kim, HR; Ahn, S; Jo, H; Kim, H; Hong, J; Lee, J; Lim, HY; Kang, WK; Kim, ST

View PubMed

TECHNOL CANCER RES T 2021 10.1177/15330338211062324 Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer Kim, H; Kim, H; Kim, R; Jo, H; Kim, HR; Hong, J; Park, JO; Park, YS; Kim, ST

View PubMed

CLIN CANCER RES 2021 10.1158/1078-0432.CCR-21-0251 Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer Kim, ST; Smith, SA; Mortimer, P; Loembe, AB; Cho, H; Kim, KM; Smith, C; Willis, S; Irurzun-Arana, I; Berges, A; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kozarewa, I; Pierce, AJ; Dean, E; Lee, J

View PubMed

CANCER DISCOV 2021 10.1158/2159-8290.CD-21-0219 Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer Kwon, M; An, M; Klempner, SJ; Lee, H; Kim, KM; Sa, JK; Cho, HJ; Hong, JY; Lee, TY; Min, YW; Kim, TJ; Min, BH; Park, WY; Kang, WK; Kim, KT; Kim, ST; Lee, J

View PubMed

CANCER MED-US 2021 10.1002/cam4.4259 Reducing tumor invasiveness by ramucirumab and TGF-beta receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model Lee, SY; Byeon, S; Ko, J; Hyung, S; Lee, IK; Li Jeon, N; Hong, JY; Kim, ST; Park, SH; Lee, J

View PubMed

J CANCER RES CLIN 2021 10.1007/s00432-021-03781-6 The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors Kim, H; Ahn, S; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST

View PubMed

THER ADV MED ONCOL 2021 10.1177/17588359211038478 Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer Hong, JY; Cho, HJ; Kim, ST; Park, YS; Shin, SH; Han, IW; Lee, JY; Heo, JS; Park, JO

View PubMed

FRONT IMMUNOL 2021 10.3389/fimmu.2021.701668 Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody Kim, N; Yu, JI; Lim, DH; Lee, J; Kim, ST; Hong, JY; Kang, WK; Jeong, WK; Kim, KM

View PubMed

J CANCER 2021 10.7150/jca.62853 When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer Kim, H; Kim, H; Lee, M; Kwon, M; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST

View PubMed

J CANCER RES THER 2021 10.4103/jcrt.JCRT_108_19 Analysis of intrapatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer Cho, JH; Sim, MH; Kim, SY; Kim, K; Lee, T; Lee, J; Kang, WK; Kim, ST

View PubMed

EXP MOL MED 2020 10.1038/s12276-020-00538-y 2020 Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer Eum¹, HH; Kwon, M; Ryu, D; Jo, A; Chung, W; Kim, N; Hong, Y; Son, DS; Kim, ST; Lee, J; Lee, HO; Park, WY

View PubMed

RADIOTHER ONCOL 2020 10.1016/j.radonc.2020.07.043 2020 Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer Analysis of the ARTIST phase III trial Yu¹, JI; Choi, C; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Nam, H; Lim, DH

View PubMed

THER ADV MED ONCOL 2020 10.1177/1758835920965842 2020 Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment Lee¹, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST

View PubMed

GASTRIC CANCER 2020 10.1007/s10120-020-01124-x 2020 Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors Kim¹, YY; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Sohn, I; Choi, D

View PubMed

THER ADV MED ONCOL 2020 10.1177/1758835920926796 2020 First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients Kim¹, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J

View PubMed

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152941 2020 CDH1 mutations in gastric cancers are not associated with family history Choi¹, S; Jang, J; Heo, YJ; Kang, SY; Kim, ST; Lee, J; Kang, WK; Kim, JW; Kim, KM

View PubMed

Transl Cancer Res 2020 10.21037/tcr-19-1876 2020 Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer Hong¹, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST

View PubMed

Transl Cancer Res 2020 10.21037/tcr.2020.04.07 2020 Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16) Byeon¹, S; Kang, MJ; Choi, YJ; Kim, YJ; Kim, M; Yun, J; Yi, SY; Kim, JY; Kim, ST; Lee, J

View PubMed

CANCERS 2020 10.3390/cancers12040943 2020 Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer Yu¹, JI; Park, HC; Lee, J; Choi, C; Kang, WK; Park, SH; Kim, ST; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Kim, S; Lim, DH

View PubMed

TARGET ONCOL 2020 10.1007/s11523-020-00713-1 2020 Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients Kim¹, J; Byeon, S; Kim, H; Yeo, JH; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST

View PubMed

TARGET ONCOL 2020 10.1007/s11523-020-00706-0 2020 Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study Byeon¹, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

View PubMed

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152881 2020 High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features Liu¹, XQ; Choi, MG; Kim, K; Kim, KM; Kim, ST; Park, SH; Cristescu, R; Peter, S; Lee, J

View PubMed

Front Oncol 2020 10.3389/fonc.2020.00314 2020 Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer Kim¹, J; Kim, B; Kang, SY; Heo, YJ; Park, SH; Kim, ST; Kang, WK; Lee, J; Kim, KM

View PubMed

ESMO OPEN 2020 10.1136/esmoopen-2020-000670 2020 Clinical scoring system for the prediction of survival of patients with advanced gastric cancer Kim¹, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J

View PubMed

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820 2020 TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer Hong¹, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK

View PubMed

VIRCHOWS ARCH 2020 10.1007/s00428-019-02653-2 2020 PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation Kim¹, HN; Jang, J; Heo, YJ; Kim, B; Jung, HR; Jang, Y; Kang, SY; Kim, ST; Lee, JY; Kang, WK; Kim, KM

View PubMed

Genome Med 2020 10.1186/s13073-020-0717-8 2020 Comprehensive pharmacogenomic characterization of gastric cancer Sa¹, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J

View PubMed

Front Oncol 2020 10.3389/fonc.2020.00225 2020 A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling Chao¹, JS; Lee, J; Kim, K; Kang, SY; Lee, T; Kim, KM; Kim, ST; Klempner, SJ; Lee, H

View PubMed

TARGET ONCOL 2020 10.1007/s11523-019-00691-z 2020 Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study Kim¹, ST; Hong, JY; Lee, JY; Park, JO; Lim, HY; Kang, WK; Park, YS

View PubMed

J ONCOL 2020 10.1155/2020/4659062 2020 Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers Lee¹, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO

View PubMed

PATHOL RES PRACT 2020 10.1016/j.prp.2019.152734 2020 Correlation between RICTOR overexpression and amplification in advanced solid tumors Bang¹, H; Ahn, S; Kim, EJ; Kim, ST; Park, H; Lee, J; Kim, KM

View PubMed

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-19-1324 2019 Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel Willis¹, J; Lefterova, MI; Artyomenko, A; Kasi, PM; Nakamura, Y; Mody, K; Catenacci, DVT; Fakih, M; Barbacioru, C; Zhao, J; Sikora, M; Fairclough, SR; Lee, H; Kim, KM; Kim, ST; Kim, J; Gavino, D; Benavides, M; Peled, N; Nguyen, T; Cusnir, M; Eskander, RN; Azzi, G; Yoshino, T; Banks, KC; Raymond, VM; Lanman, RB; Chudova, DI; Talasaz, A; Kopetz, S; Lee, J; Odegaard, JI

View PubMed

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-19-1704 2019 Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma Maron¹, SB; Chase, LM; Lomnicki, S; Kochanny, S; Moore, KL; Joshi, SS; Landron, S; Johnson, J; Kiedrowski, LA; Nagy, RJ; Lanman, RB; Kim, ST; Lee, J; Catenacci, DVT

View PubMed

INT J CANCER 2019 10.1002/ijc.32228 2019 Bridging genomics and phenomics of gastric carcinoma Cho¹, J; Ahn, S; Son, DS; Kim, NKD; Lee, KW; Kim, S; Lee, J; Park, SH; Park, JO; Kang, WK; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, KM

View PubMed

ONCOLOGIST 2019 10.1634/theoncologist.2019-0121 2019 FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape Klempner¹, SJ; Madison, R; Pujara, V; Ross, JS; Miller, VA; Ali, SM; Schrock, AB; Kim, ST; Maron, SB; Dayyani, F; Catenacci, DVT; Lee, J; Chao, J

View PubMed

TRANSL ONCOL 2019 10.1016/j.tranon.2019.07.017 2019 Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study Kwon¹, D; Kim, B; Shin, HC; Kim, EJ; Ha, SY; Jang, KT; Kim, ST; Lee, J; Kang, WK; Park, JO; Kim, KM

View PubMed

Front Oncol 2019 10.3389/fonc.2019.01327 2019 Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening Lim¹, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J

View PubMed

J Cancer 2019 10.7150/jca.37610 2019 Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial Kim¹, ST; Oh, SY; Lee, J; Kang, JH; Lee, HW; Lee, MA; Sohn, BS; Hong, JH; Park, YS; Park, JO; Lim, HY

View PubMed

J IMMUNOTHER 2019 10.1097/CJI.0000000000000283 2019 LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target Lee¹, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST

View PubMed

ANTICANCER RES 2019 10.21873/anticanres.13785 2019 Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer Yu¹, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

View PubMed

SCI REP-UK 2019 10.1038/s41598-019-51981-5 2019 Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients Bray¹, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C

View PubMed

CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442 2019 Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Lee¹, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK

View PubMed

ONCOLOGIST 2019 10.1634/theoncologist.2019-0221 2019 A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities Kim¹, YS; Ji, JH; Oh, SY; Lee, S; Huh, SJ; Lee, JH; Song, KH; Son, CH; Roh, MS; Lee, GW; Lee, J; Kim, ST; Kim, CK; Jang, JS; Hwang, IG; Ahn, HK; Park, LC; Oh, SY; Kim, SG; Lee, SC; Lim, DH; Lee, SI; Kang, JH

View PubMed

Transl Cancer Res 2019 10.21037/tcr.2019.09.27 2019 Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs Cho¹, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

View PubMed

THER ADV MED ONCOL 2019 10.1177/1758835919871126 2019 Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group Yoo¹, C; Im, HS; Kim, KP; Oh, DY; Lee, KH; Chon, HJ; Kim, JH; Kang, M; Kim, I; Lee, GJ; Oh, SY; Choi, Y; Choi, HJ; Kim, ST; Park, JO; Ryoo, BY

View PubMed

BMC CANCER 2019 10.1186/s12885-019-6030-5 2019 Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody Lee¹, J; Lee, SJ; Kim, K; Kim, ST; Lee, J

View PubMed

PATHOL RES PRACT 2019 10.1016/j.prp.2019.152434 2019 CCNE1 amplification is associated with liver metastasis in gastric carcinoma Kim¹, B; Shin, HC; Heo, YJ; Ha, SY; Jang, KT; Kim, ST; Kang, WK; Lee, J; Kim, KM

View PubMed

CANCER RES TREAT 2019 10.4143/crt.2018.379 2019 A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients Kim¹, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK

View PubMed

Am J Transl Res 2019 2019 Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification Kim¹, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J

View PubMed

CANCER RES TREAT 2019 10.4143/crt.2018.401 2019 Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols Yu¹, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K

View PubMed

J MOL DIAGN 2019 10.1016/j.jmoldx.2019.02.007 2019 Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing A Direct Comparison Study with Immunohistochemistry Choi¹, S; Chu, J; Kim, B; Ha, SY; Kim, ST; Lee, J; Kang, WK; Han, H; Sohn, I; Kim, KM

View PubMed

J Cancer 2019 10.7150/jca.30355 2019 The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma Yoon¹, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

View PubMed

J Cancer 2019 10.7150/jca.30257 2019 High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer Kim¹, Y; Byeon, SJ; Hur, J; Lee, K; Kim, D; Ahn, JH; Lee, SH; You, WK; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J

View PubMed

ONCOLOGY-BASEL 2019 10.1159/000499628 2019 Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial Miceli¹, R; An, J; Di Bartolomeo, M; Morano, F; Kim, ST; Park, SH; Choi, MG; Lee, JH; Raimondi, A; Fuca, G; Sohn, TS; Bae, JM; Kim, S; Lim, DH; Kang, WK; Kim, KM; Pietrantonio, F; Lee, J

View PubMed

ANN ONCOL 2019 10.1093/annonc/mdz058 2019 Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial Kim¹, ST; Kang, JH; Lee, J; Lee, HW; Oh, SY; Jang, JS; Lee, MA; Sohn, BS; Yoon, SY; Choi, HJ; Hong, JH; Kim, MJ; Kim, S; Park, YS; Park, JO; Lim, HY

View PubMed

PLoS One 2019 10.1371/journal.pone.0215080 2019 Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system Cho¹, JH; Kim, JS; Kim, ST; Hong, JY; Park, JO; Park, YS; Nam, DH; Lee, DW; Lee, J

View PubMed

TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009 2019 Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial Kim¹, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J

View PubMed

Front Oncol 2019 10.3389/fonc.2019.00212 2019 Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort Lee¹, J; Franovic, A; Shiotsu, Y; Kim, ST; Kim, KM; Banks, KC; Raymond, VM; Lanman, RB

View PubMed

J Cancer 2019 10.7150/jca.29106 2019 The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer Yoon¹, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

View PubMed

PATHOL RES PRACT 2019 10.1016/j.prp.2018.11.010 2019 MET is overexpressed in microsatellite instability-high gastric carcinoma Sim¹, J; Heo, YJ; Bae, H; Shin, HC; Kim, B; Cho, J; Kim, ST; Lee, J; Kang, WK; Kim, KM

View PubMed

CANCER CHEMOTH PHARM 2019 10.1007/s00280-018-3753-y 2019 Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer Oh¹, SY; Lee, S; Huh, SJ; Lee, J; Kim, ST; Park, SH; Lim, HY; Kang, WK; Kang, BW; Kim, JG; Lee, HJ; Kim, JH; Kang, JH; Kim, H

View PubMed

ANN ONCOL 2019 10.1093/annonc/mdy550 2019 Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer Sundar¹, R; Huang, KK; Qamra, A; Kim, KM; Kim, ST; Kang, WK; Tan, ALK; Lee, J; Tan, P

View PubMed

Oncoimmunology 2019 10.1080/2162402X.2018.1544442 2019 PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer Angell¹, HK; Lee, J; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK; Sharpe, A; Ogden, J; Davenport, A; Hodgson, DR; Barrett, JC; Kilgour, E

View PubMed

OncoTargets and therapy 2019 10.2147/OTT.S187621 2019 The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice Yoon¹, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

View PubMed

J Gastric Cancer 2018 10.5230/jgc.2018.18.e34 2018 Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial Kim¹, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH

View PubMed

BMC CANCER 2018 10.1186/s12885-018-4995-0 2018 Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line Kim¹, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO

View PubMed

RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002 2018 Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer Yu¹, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

View PubMed

SCI REP-UK 2018 10.1038/s41598-018-34858-x 2018 SEPROGADIC-serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy Ahn¹, HS; Sohn, TS; Kim, MJ; Cho, BK; Kim, SM; Kim, ST; Yi, EC; Lee, C

View PubMed

NAT GENET 2018 10.1038/s41588-018-0209-6 2018 Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy Lee¹, JK; Liu, ZQ; Sa, JK; Shin, S; Wang, JG; Bordyuh, M; Cho, H; Elliott, O; Chu, T; Choi, SW; Rosenbloom, DIS; Lee, IH; Shin, YJ; Kang, HJ; Kim, D; Kim, SY; Sim, MH; Kim, J; Lee, T; Seo, YJ; Shin, H; Lee, M; Kim, SH; Kwon, YJ; Oh, JW; Song, M; Kim, M; Kong, DS; Choi, JW; Seol, HJ; Lee, JI; Kim, ST; Park, JO; Kim, KM; Song, SY; Lee, JW; Kim, HC; Lee, JE; Choi, MG; Seo, SW; Shim, YM; Zo, JI; Jeong, BC; Yoon, Y; Ryu, GH; Kim, NKD; Bae, JS; Park, WY; Lee, J; Verhaak, RGW; Iavarone, A; Lee, J; Rabadan, R; Nam, DH

View PubMed

J Cancer 2018 10.7150/jca.26068 2018 Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation Lee¹, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST

View PubMed

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013 2018 c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival Lee¹, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

View PubMed

NAT MED 2018 10.1038/s41591-018-0101-z 2018 Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer Kim¹, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK

View PubMed

J Cancer 2018 10.7150/jca.26256 2018 NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines Kim¹, SY; Oh, SO; Kim, K; Lee, J; Kang, S; Kim, KM; Lee, W; Kim, ST; Nam, DN

View PubMed

J Cancer 2018 10.7150/jca.24948 2018 Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial Lim¹, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

View PubMed

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005 2018 Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer Lee¹, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS

View PubMed

ANN ONCOL 2018 10.1093/annonc/mdy090 2018 RET fusions in a small subset of advanced colorectal cancers at risk of being neglected Pietrantonio¹, F; Di Nicolantonio, F; Schrock, AB; Lee, J; Morano, F; Fuca, G; Nikolinakos, P; Drilon, A; Hechtman, JF; Christiansen, J; Gowen, K; Frampton, GM; Gasparini, P; Rossini, D; Gigliotti, C; Kim, ST; Prisciandaro, M; Hodgson, J; Zaniboni, A; Chiu, VK; Milione, M; Patel, R; Miller, V; Bardelli, A; Novara, L; Wang, L; Pupa, SM; Sozzi, G; Ross, J; Di Bartolomeo, M; Bertotti, A; Ali, S; Trusolino, L; Falcone, A; de Braud, F; Cremolini, C

View PubMed

ANN ONCOL 2018 10.1093/annonc/mdy034 2018 Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients Kim¹, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J

View PubMed

TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007 2018 The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer Lee¹, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY

View PubMed

J Cancer 2018 10.7150/jca.25132 2018 The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer Kim¹, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO

View PubMed

ONCOLOGIST 2018 10.1634/theoncologist.2017-0528 2018 Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors Lee¹, KW; Lee, DH; Kang, JH; Park, JO; Kim, SH; Hong, YS; Kim, ST; Oh, DY; Bang, YJ

View PubMed

J NATL CANCER I 2017 10.1093/jnci/djx089 2017 ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer Pietrantonio¹, F; Di Nicolantonio, F; Schrock, AB; Lee, J; Tejpar, S; Sartore-Bianchi, A; Hechtman, JF; Christiansen, J; Novara, L; Tebbutt, N; Fuca, G; Antoniotti, C; Kim, ST; Murphy, D; Berenato, R; Morano, F; Sun, J; Min, BS; Stephens, PJ; Chen, M; Cremolini, C

View PubMed

ONCOTARGET 2017 10.18632/oncotarget.22394 2017 MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines Kim¹, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J

View PubMed

ONCOTARGET 2017 10.18632/oncotarget.18182 2017 Correlation between MEK signature and Ras gene alteration in advanced gastric cancer Ahn¹, S; Brant, R; Sharpe, A; Dry, JR; Hodgson, DR; Kilgour, E; Kim, K; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J

View PubMed

ONCOTARGET 2017 10.18632/oncotarget.3750 2017 MerTK is a novel therapeutic target in gastric cancer Yi¹, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J

View PubMed

Oncoimmunology 2017 10.1080/2162402X.2017.1356150 2017 Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity Park¹, C; Cho, J; Lee, J; Kang, SY; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, ST; Park, SH; Park, JO; Kang, WK; Sohn, I; Jung, SH; Kang, MS; Kim, KM

View PubMed

ONCOLOGIST 2017 10.1634/theoncologist.2017-0129 2017 Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial Go¹, SI; Koo, DH; Kim, ST; Song, HN; Kim, RB; Jang, JS; Oh, SY; Lee, KH; Lee, SI; Kim, SG; Park, LC; Lee, SC; Park, BB; Ji, JH; Yi, SY; Lee, YG; Yun, J; Bruera, E; Hwang, IG; Kang, JH

View PubMed

NAT COMMUN 2017 10.1038/s41467-017-01470-y 2017 Prevalence and detection of low-allele-fraction variants in clinical cancer samples Shin¹, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY

View PubMed

ONCOLOGIST 2017 10.1634/theoncologist.2017-0020 2017 Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials Kim¹, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J

View PubMed

Clin Transl Oncol 2017 10.1007/s12094-017-1662-x 2017 Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma Cho¹, J; Kim, SY; Kim, YJ; Sim, MH; Kim, ST; Kim, NKD; Kim, K; Park, W; Kim, JH; Jang, KT; Lee, J

View PubMed

ONCOTARGET 2017 10.18632/oncotarget.20492 2017 Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy Kim¹, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J

View PubMed

ONCOTARGET 2017 10.18632/oncotarget.18168 2017 The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs Kim¹, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

View PubMed

ONCOTARGET 2017 10.18632/oncotarget.19985 2017 Development of mesenchymal subtype gene signature for clinical application in gastric cancer Lee¹, J; Cristescu, R; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK

View PubMed

J Cancer 2017 10.7150/jca.19458 2017 The Impact of Cetuximab Plus AKT- or mTOR-Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation Kim¹, JS; Kim, JE; Kim, K; Lee, J; Park, JO; Lim, HY; Park, YS; Kang, WK; Kim, ST

View PubMed

J Cancer 2017 10.7150/jca.18286 2017 The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer Kim¹, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS

View PubMed

EUR RADIOL 2017 10.1007/s00330-016-4644-4 2017 Disappearing or residual tiny (ae<currency>5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required? Kim¹, SS; Song, KD; Kim, YK; Kim, HC; Huh, JW; Park, YS; Park, JO; Kim, ST

View PubMed

J Cancer 2017 10.7150/jca.19582 2017 MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines Kim¹, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

View PubMed

TUMORI 2017 10.5301/tj.5000666 2017 Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer Yu¹, JI; Park, HC; Lim, DH; Park, JO; Park, YS; Kim, ST; Choi, SH; Choi, DW; Han, IW; Heo, JS

View PubMed

BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6. 2017 Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy Kim ST1¹, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.

View PubMed

Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. 2017 Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition Kim ST1¹, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.

View PubMed

Oncotarget. 2017 Feb 21;8(8):13320-13328. doi: 10.18632/oncotarget.14519. 2017 Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability Cho J1¹, Lee J2, Bang H3, Kim ST2, Park SH2, An JY4, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kang WK2, Kim S4, Kim KM3.

View PubMed

Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362. 2017 Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer Kim JH1¹, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.

View PubMed

Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788. 2017 Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion Kim SY1¹, Ahn T2, Bang H3, Ham JS1, Kim J1, Kim ST1, Jang J1, Shim M1, Kang SY3, Park SH1, Min BH4, Lee H4, Kang WK1, Kim KM3, Park W2,5, Lee J1.

View PubMed

Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. 2017 The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors Lim SH1¹, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.

View PubMed

Am J Ther. 2016 Nov/Dec;23(6):e1449-e1455. 2016 A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin Lee SY1¹, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Tae Kim S.

View PubMed

Transl Oncol. 2016 Oct;9(5):466-471. doi: 10.1016/j.tranon.2016.08.009. 2016 Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma Cho J1¹, Lee J1, Kim J1, Kim ST1, Lee S1, Kim SY1, Ha SY2, Park CK3, Lim HY4.

View PubMed

J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016. 2016 To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients Lee H1¹, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.

View PubMed

Oncotarget. 2016 Sep 20;7(38):62676-62686. doi: 10.18632/oncotarget.10445. 2016 Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy Yu JI1¹, Lee H2, Park HC1, Choi DH1, Choi YL3, Do IG4, Kim HC5, Lee WY5, Yun SH5, Cho YB5, Huh JW5, Park YA6, Park YS6, Park JO6, Kim ST6, Park W1.

View PubMed

Mod Pathol. 2016 Sep;29(9):1095-103. doi: 10.1038/modpathol.2016.96. Epub 2016 May 27. 2016 FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival Ahn S1¹,2, Lee J3, Hong M4, Kim ST3, Park SH3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Jung SH6, Kang WK3, Kim KM1,2.

View PubMed

Mol Diagn Ther. 2016 Aug;20(4):375-83. doi: 10.1007/s40291-016-0205-4. 2016 A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer Ahn S1¹,2, Hong M3, Van Vrancken M4, Lyou YJ2, Kim ST5, Park SH5, Kang WK5, Park YS5, Jung SH6, Woo M6, Lee J7, Kim KM8,9.

View PubMed

Transl Oncol. 2016 Jun;9(3):197-202. doi: 10.1016/j.tranon.2016.03.008. Epub 2016 May 12. 2016 BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells Kim HK1¹, Kim SY1, Lee SJ1, Kang M1, Kim ST1, Jang J1, Rath O2, Schueler J2, Lee DW3, Park WY4, Kim SJ5, Park SH1, Lee J6.

View PubMed

Onco Targets Ther. 2016 Jun 1;9:3307-12. doi: 10.2147/OTT.S104511. eCollection 2016. 2016 The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer Choi YJ1¹, Chang WJ1, Shin SW1, Park KH1, Kim ST2, Kim YH1.

View PubMed

J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16. 2016 Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin) Kim ST1¹, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.

View PubMed

Transl Oncol. 2016 Jun;9(3):173-8. doi: 10.1016/j.tranon.2016.01.007. Epub 2016 Apr 22. 2016 Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing Yoo KH1¹, Kim NK2, Kwon WI3, Lee C2, Kim SY1, Jang J1, Ahn J1, Kang M1, Jang H1, Kim ST1, Ahn S4, Jang KT4, Park YS1, Park WY5, Lee J6, Heo JS7, Park JO8.

View PubMed

J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016. 2016 Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era Kim ST1¹, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.

View PubMed

Cancer Chemother Pharmacol. 2016 May;77(5):979-85. doi: 10.1007/s00280-016-3014-x. Epub 2016 Mar 26. 2016 Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma Kim YS1¹, Hwang IG2, Park SE3, Go SI4, Kang JH4, Park I1, Oh SY5, Ji JH6, Song HN7, Park SH7, Kim ST7, Park JO7.

View PubMed

Medicine (Baltimore). 2016 May;95(19):e3534. doi: 10.1097/MD.0000000000003534. 2016 The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution Kim ST1¹, Ha SY, Lee J, Hong SN, Chang DK, Kim YH, Park YA, Huh JW, Cho YB, Yun SH, Lee WY, Kim HC, Park YS.

View PubMed

Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10. 2016 A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology Yi JH1¹, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.

View PubMed

Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526. 2016 Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment Song HN1¹,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.

View PubMed

Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175. 2016 Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Kim ST1¹, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.

View PubMed

J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016. 2016 The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs Kim ST1¹, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.

View PubMed

BMC Cancer. 2016 Feb 18;16:120. doi: 10.1186/s12885-016-2141-4. 2016 The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis Kim HS1¹,2, Heo JS3, Lee J4, Lee JY5, Lee MY6, Lim SH7, Lee WY8, Kim SH9, Park YA10, Cho YB11, Yun SH12, Kim ST13, Park JO14, Lim HY15, Choi YS16, Kwon WI17, Kim HC18, Park YS19.

View PubMed

Oncotarget. 2016 Jan 26;7(4):4024-35. doi: 10.18632/oncotarget.6602. 2016 Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors Park C1¹, Ha SY1, Kim ST2, Kim HC3, Heo JS3, Park YS2, Lauwers G4, Lee J2, Kim KM1.

View PubMed

Cancer Res Treat. 2016 Jan;48(1):153-61. doi: 10.4143/crt.2014.183. Epub 2015 Mar 7. 2016 The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors Kim M1¹, Lee S2, Lee J2, Park SH2, Park JO2, Park YS2, Kang WK2, Kim ST2.

View PubMed

Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432. 2015 PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA Kim ST1¹, Lira M2, Deng S2, Lee S1, Park YS1, Lim HY1, Kang WK1, Mao M3, Heo JS4, Kwon W4, Jang KT5, Lee J1,6, Park JO1,6.

View PubMed

Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494. 2015 NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line Lee SJ1¹, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.

View PubMed

Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27. 2015 A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer Lim SH1¹, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.

View PubMed

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465. 2015 Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Kim ST1¹, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.

View PubMed

Cancer Res Treat. 2015 Oct;47(4):796-803. doi: 10.4143/crt.2014.106. Epub 2015 Jan 30. 2015 Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer Kim ST1¹,2, Chang WJ1, Jin L3, Sung JS3, Choi YJ1, Kim YH1,3.

View PubMed

Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. 2015 The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST1¹, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.

View PubMed

Cancer Res Treat. 2015 Oct;47(4):790-5. doi: 10.4143/crt.2014.126. Epub 2014 Dec 2. 2015 Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer Kim ST1¹, Kim TW2, Kim KP2, Kim TY3, Han SW3, Lee JY1, Lim SH1, Lee MY1, Kim H1, Park YS1.

View PubMed

J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5. 2015 Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses Park SH1¹, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.

View PubMed

BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y. 2015 Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan Kim ST¹, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC

View PubMed

Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20. 2015 Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial Yu JI1¹, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.

View PubMed

Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151. 2015 Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer Lee SJ1¹, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.

View PubMed

Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627. 2015 Patient-derived cell models as preclinical tools for genome-directed targeted therapy Lee JY1¹, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.

View PubMed

Oncotarget. 2015 Sep 15;6(27):24320-32. 2015 Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening Lee J1¹, Kim HC2, Hong JY3, Wang K4, Kim SY1, Jang J1, Kim ST1, Park JO1, Lim HY1, Kang WK1, Park YS1, Lee J1, Lee WY2, Park YA2, Huh JW2, Yun SH2, Do IG5, Kim SH5, Balasubramanian S4, Stephens PJ4, Ross JS4,6, Li GG7, Hornby Z7, Ali SM4, Miller VA4, Kim KM5,8, Ou SH9.

View PubMed

Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721. 2015 Gastrointestinal malignancies harbor actionable MET exon 14 deletions Lee J1¹,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.

View PubMed

Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001. 2015 Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer Kim ST1¹, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.

View PubMed

BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y. 2015 Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer Kim ST1¹, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.

View PubMed

Clin Transl Oncol. 2015 Jun;17(6):462-8. doi: 10.1007/s12094-014-1258-7. Epub 2014 Dec 2. 2015 The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer Kim ST1¹, Do IG, Lee J, Sohn I, Kim KM, Kang WK.

View PubMed

Nat Med. 2015 May;21(5):449-56. doi: 10.1038/nm.3850. Epub 2015 Apr 20. 2015 Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes Cristescu R1¹, Lee J2, Nebozhyn M1, Kim KM3, Ting JC4, Wong SS4, Liu J4, Yue YG4, Wang J4, Yu K4, Ye XS4, Do IG3, Liu S5, Gong L5, Fu J6, Jin JG6, Choi MG7, Sohn TS7, Lee JH7, Bae JM7, Kim ST2, Park SH2, Sohn I8, Jung SH8, Tan P9, Chen R1, Hardwick J1, Kang WK2, Ayers M1, Hongyue D1, Reinhard C4, Loboda A1, Kim S7, Aggarwal A4.

View PubMed

Sci Rep. 2015 Mar 19;5:9289. doi: 10.1038/srep09289. 2015 The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer Lee JY1¹, Hong M2, Kim ST1, Park SH1, Kang WK1, Kim KM2, Lee J1.

View PubMed

Transl Oncol. 2015 Feb;8(1):40-6. doi: 10.1016/j.tranon.2014.12.003. 2015 Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer Kim ST1¹, Jang KT2, Lee J1, Jang HM3, Choi HJ4, Jang HL1, Park SH1, Park YS1, Lim HY1, Kang WK1, Park JO5.

View PubMed

Sci Rep. 2014 Dec 23;4:7592. doi: 10.1038/srep07592. 2014 Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer Yi JH1¹, Do IG2, Jang J3, Kim ST3, Kim KM4, Park SH3, Park JO3, Park YS3, Lim HY3, Kang WK3, Lee J3.

View PubMed

BMC Cancer. 2014 Nov 26;14:883. doi: 10.1186/1471-2407-14-883. 2014 S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial Kim ST¹, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Lee JW, Jo SJ, Park YS1.

View PubMed

Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23. 2014 Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification Kim ST1¹, Jang HL2, Lee SJ1, Lee J1, Choi YL3, Kim KM3, Cho J4, Park SH1, Park YS1, Lim HY1, Yashiro M5, Kang WK1, Park JO6.

View PubMed

Eur J Cancer. 2014 Nov;50(16):2822-30. doi: 10.1016/j.ejca.2014.08.005. Epub 2014 Sep 15. 2014 Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study Kim ST1¹, Kang JH2, Lee J1, Park SH1, Park JO1, Park YS1, Lim HY1, Hwang IG3, Lee SC4, Park KW5, Lee HR6, Kang WK7.

View PubMed

PLoS One. 2014 Nov 5;9(11):e111693. doi: 10.1371/journal.pone.0111693. eCollection 2014. 2014 High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer Kim S1¹, Lee J2, Hong ME3, Do IG3, Kang SY1, Ha SY1, Kim ST2, Park SH2, Kang WK2, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kim S4, Kim DH5, Kim KM3.

View PubMed

Cancer?Genomics Proteomics.?2014 Sep-Oct;11(5):259-66. 2014 Transcriptome Analysis of CD133-positive Stem Cells and Prognostic Value of Survivin in Colorectal Cancer Kim ST1¹,?Sohn I2,?DO IG3,?Jang J4,?Kim SH3,?Jung IH5,?Park JO1,?Park YS1,?Talasaz A6,?Lee J1,?Kim HC7.

View PubMed

Cancer Res Treat. 2014 Jan;46(1):48-54. doi: 10.4143/crt.2014.46.1.48. Epub 2014 Jan 15. 2014 Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients Kim ST1¹, Park KH2, Shin SW2, Kim YH2.

View PubMed

날짜					목 01	금 02	토 03	일 04	월 05	화 06	수 07	목 08	금 09	토 10	일 11	월 12	화 13	수 14	목 15	금 16	토 17	일 18	월 19	화 20	수 21	목 22	금 23	토 24	일 25	월 26	화 27	수 28	목 29	금 30	토 31
오전
오후

날짜	일 01	월 02	화 03	수 04	목 05	금 06	토 07	일 08	월 09	화 10	수 11	목 12	금 13	토 14	일 15	월 16	화 17	수 18	목 19	금 20	토 21	일 22	월 23	화 24	수 25	목 26	금 27	토 28	일 29	월 30
오전
오후

게재일	2014-10-22
발표년월	2012-05	구분	국내
학술지	가정의학회지
논문명(국문)
논문명(영문)
요약문	td	발행정보	2010;31(10):778-785
책임저자	이정권
저자	박주현, 이선진, 곽정임, 심재용, 이정권	제 1저자	박주현
초록첨부	test
논문첨부

혈액종양내과 김승태 교수

학력

경력

[언론기사]

항암요법연구회 회원들, ASCO서 25건 발표

[언론기사]

삼성서울병원 "위암 '유전체 분석 기반 치료' 효과 입증"

[언론기사]

입센코리아 신경내분비종양 치료 시장에 도전